Summary
What is known: Currently, medication bottles with an electronic cap are frequently used to measure medication adherence. This system is termed medication event monitoring system (MEMS). To our knowledge, the optimal method to summarize data from MEMS has not yet been determined.
Objective: Look for best practices on how to quantify adherence data from MEMS.
Methods: Review of PubMed, Embase and Cochrane databases for the articles on medication adherence with MEMS.
Results: Of 1493 identified articles, 207 were included in this review. The MEMS cap was used for a median of 3 months (IQR: 4; range: 1 week to 24 months) in various health conditions. Many different outcome measures were used. Most studies computed an adherence score, expressed as the percentage of days on which the correct dose of medication was taken. The threshold to mark people as adherent was most frequently, arbitrarily, set at 80% (range: 67%-95%). We found no data to support a specific threshold.
Discussion:
Although the commonly used definition of adherence has face validity, we found no validation studies, and not all studies used the same cut-off for adherence. Ideally, a cut-off should be defined and validated in the context of the specific drug and its pharmacokinetic and dynamic characteristics, and perhaps other contextual factors, rather than generically. In addition, there was large heterogeneity in the definition of what "correct intake" of medication is.
What is new and conclusion: Outcome measures for MEMS data lacked standardization, and no demonstrable effort to validate any definition against a relevant clinical outcome is available. Consensus on the definition of adherence is urgently needed.
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| OBJEC TIVE
The rationale for this narrative literature review is to enable an informed choice on the preferred methods to summarize the adherence data from the currently running GLORIA trial. In this literature review, the methods to summarize MEMS data will be described. An additional search was performed to find validation studies that compared the definitions that are used to summarize MEMS data.
| ME THODS

| Search strategy
| Data extraction
One investigator (LH) extracted the following information: design of the study, sample size, mean age and health condition of participants, duration of monitoring and methods to calculate adherence (Appendix S2). Study results (eg, the effects of interventions on adherence) and the quality assessment of the study were not the object of study and thus not extracted.
| RE SULTS
| Study selection
The search identified 1493 articles, of which 1127 off-topic articles and 48 double entries were excluded after screening of title and abstract. Of the remainder, 71 articles were excluded because the subject was not about electronic monitoring (n = 34), the full text was not available (n = 29) or the article was not written in English or Dutch (n = 8). Of the 247 articles read in full, 40 contained no useful information for this review. In the end, 207 articles were included (see Figure 1 and Appendix S1). No validation studies were identified.
| Study characteristics
Most of the included studies had a prospective design; about one third was a randomized controlled trial. The sample size was a median of 83 patients (IQR: 106, range: 4-3004). The mean age of the patients was 52 (SD 46) years, and 57% of them were male. A total of 62 different health conditions were studied. Most patients had HIV (29%) or heart failure (10%) ( Table 1 ). The MEMS cap was used for a median of 3 months (IQR: 4; range: 1 week to 24 months).
| Outcome measures
Medication event monitoring system systems can supply a wealth of information, including dates and times of openings, the intervals between two consecutive doses and a graph which presents the number of cap openings per day. 3 The included studies reported several outcome measures (Table 1) . Most studies computed an adherence score (n = 156), expressed as the percentage of days on which the correct dose of medication was taken. 4 The choice of outcome measure was independent of the health condition (results not shown).
In 76 studies, a threshold was defined on the adherence score to mark people as adherent or nonadherent. The thresholds ranged from 67% to 95%, and in half of the studies, it was 80%; most frequently chosen alternatives included thresholds of 90% (n = 13), 88% (n = 8) and 95% (n = 8).
The dose compliance (ie, in drugs with multiple dosing on a day the mean percentage of doses taken correctly per day) and the timing compliance (ie, the percentage of doses taken at the appropriate time) were also calculated in several studies (in 14% and 23%, respectively). The time frame ranged from 2 to 4 hours in studies on glaucoma, 5-8 diabetes mellitus, 9 HIV 9,10 and schizophrenia.
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A few studies (4%) calculated "drug holidays," that is periods of a certain number of days on which the medication bottle was not opened, followed by a bottle opening. 12, 13 In contrast, Israni et al excluded patients who had fewer than 14 days of usable adherence data. 14 Olds et al considered MEMS data as missing if the bottle was not opened for a certain number of consecutive days. 15 In some studies, multiple openings were counted as 1 opening if the bottle was opened several times within 15 16 or 30 minutes 17,18 of the previous opening. Unexpected openings outside this time window were assumed to represent a taken dose.
16
| D ISCUSS I ON
In this narrative literature review (the first to our knowledge), we looked for best practices on how to quantify adherence. We chose a broad scope, but were somewhat limited due to language restrictions and the unavailability of some studies.
The adherence score, that is the percentage of days correctly dosed, and its cut-off of 80% were the most frequently used quantification and definition of sufficient adherence. Although this definition has face validity, we found no validation studies, and not all studies used this cut-off. Ideally, a cut-off should be defined and validated in the context of the specific drug and its pharmacokinetic and dynamic characteristics, and perhaps other contextual factors, rather than generically.
In addition, there was large heterogeneity in the definition of what "correct intake" is. This included definitions of the allowable time window between doses, overdosing and dealing with consecutive days with no bottle openings. Some studies mark these periods as drug holidays, whereas other studies consider these periods as missing data. Any definition should ideally be tested/ validated against a clinically relevant outcome to be of use in the clinic. In addition, an array of definitions for adherence was used, indicating an urgent need for a consensus effort. Such efforts have been successful in rheumatology 19 and are gaining traction in other fields. 20 It is also remarkable that for so many health conditions, adherence studies with MEMS are rare or even nonexistent. Most studies were about HIV, heart failure, hypertension or schizophrenia. We did not find any relation between these health conditions and the methods that were used to summarize the MEMS data. MEMS is often seen as the reference standard to measure medication adherence, but it still assumes that one bottle opening equals the intake of one medication dose, 3 a simplification that cannot be easily checked.
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For example, a patient could open the bottle and either not take any or more than the appropriate dose. Validation of MEMS data may become possible with compliance capsules with an ingestion sensor. 21, 22 This is a new method, where the sensor signals when the drug is taken. Compliance capsules have the potential to become the new reference standard in the future.
| WHAT IS NE W AND CON CLUS I ON
While adherence is clearly critical to treatment success, this review demonstrates a lack of consensus on a concrete working definition to be used in studies and no demonstrable effort to validate any one No useful informaƟon 40 definition against a relevant clinical outcome. Progress in this field is unlikely unless these issues are addressed. Kidney transplantation 4
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Adherence score: percentage of days on which the correct dose was taken
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